“As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”
-Rich Uhlig, Founder & CEO
-Rich Uhlig, Founder & CEO
The Clarifi® Dx diagnostic platform leverages new discoveries in epigenetics and the microbiome to provide first of its kind diagnostic solutions to many of today’s critical health care challenges. Developed in medical research labs at SUNY Upstate Medical University and Penn State College of Medicine, Clarifi ASD® recently launched commercially in the US. It is the first of its kind saliva test for autism spectrum disorder. Quadrant has also developed and launched three COVID-19 solutions in partnership with with SUNY Upstate Medical University.
We develop saliva-based, RNA diagnostic solutions for autism spectrum disorder, Parkinson’s disease, concussion injury, and surveillance solutions for COVID-19. We recently launched Clarifi ASD®, the world’s first saliva test for autism.
In response to the COVID-19 pandemic, we leveraged our expertise in RNA analysis and became actively engaged in several major COVID-19 testing projects that involve individual testing, group (pooled) surveillance testing, and municipal wastewater surveillance.
We have assembled an experienced management team led by former Morgan Stanley Bank CEO Rich Uhlig, as well as an expert medical advisory board comprised of recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.
We have assembled a seasoned management team, as well as an experienced clinical advisory board comprising recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.
Our Board of Directors is composed of individuals with substantial knowledge and experience in the areas of finance, law, medicine, operations, intellectual property, and sales.